Maintaining Antiviral Efficacy After Switching to Generic Entecavir 1 mg for Chronic Hepatitis B
Status:
Active, not recruiting
Trial end date:
2020-12-31
Target enrollment:
Participant gender:
Summary
Entecavir 1 mg is commonly used in patients with chronic hepatitis B (CHB) patients with
previous antiviral resistance. This study evaluates the efficacy and safety of switching to
generic entecavir 1 mg (Baracle®, Dong-A Science Technology) in CHB patients taking brand
name entecavir 1 mg (Baraclude®, Bristol-Myers Squibb) alone or in combination with other
nucleos(t)ide analogues after the development of antiviral resistance.
The primary aim is virological response (<20 IU/mL) at 12 months